<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="lead">
            <roleset id="lead.01" name="resulted&#x0A;" wordnet="3">
                <roles>
                    <role n="0" descr="factors&#x0A;" />
                    <role n="2" descr="result&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations that lead to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations that led to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations which lead to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations which led to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription can lead us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription leads us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription led us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Closer examination of the putative signal transduction pathway modulating htrA transcription will lead us to the identification of two new genes.</text>
                    <arg n="0">Closer examination of the putative signal transduction pathway modulating htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D can lead to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D has led to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D is able to lead to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D may lead to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Crl stimulates the activity of sigma (S) lead to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Crl stimulates the activity of sigma (S) led to an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase.</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Disruption of the SNU246 gene in yeast is lethal and can lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Disruption of the SNU246 gene in yeast was lethal and could lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Disruption of the SNU246 gene in yeast was lethal and led to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Disruption of the SNU246 gene in yeast was lethal and might lead to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction could lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction had led to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction was able to lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that DNA (nCaRE)-ref1 interaction is able to lead to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggests that DNA (nCaRE)-ref1 interaction leads to C2+e-mediated transcriptional suppression.</text>
                    <arg n="0">DNA (nCaRE)-ref1 interaction</arg>
                    <arg n="1">C2+e-mediated transcriptional suppression</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Genetic deficiency of GM2 activator can lead to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Genetic deficiency of GM2 activator has led to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Genetic deficiency of GM2 activator is leading to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Genetic deficiency of GM2 activator led to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% decrease in expression when cells are cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite has led to a 45% decrease in expression when cells were cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression when cells are cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression when cells were cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% decrease in expression when cells are going to be cultivated in rich medium.</text>
                    <arg n="0">Growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, can lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, could lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, has led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, is able to lead to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, which led to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and has led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivated the 5 cleavage event of splicing and will lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivates the 5 cleavage event of splicing and is able to lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>The loss of TreR function can lead to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>The loss of TreR function has led to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>The loss of TreR function leads to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>The loss of TreR function will lead to derepression of treB encoding an enzymeIITre of the PTS for trehalose and of treC encoding TreC, the cytoplasmic trehalose-6-phosphate hydrolase.</text>
                    <arg n="0">The loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>The mutations identified include: two frameshifts and a splice site mutation that lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>The mutations identified include: two frameshifts and a splice site mutation which have led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>The mutations identified include: two frameshifts and a splice site mutation which lead to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>The mutations identified include: two frameshifts and a splice site mutation which led to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>The splice mutation in 5 end of intron 5 can lead to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>The splice mutation in 5 end of intron 5 has led to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>The splice mutation in 5 end of intron 5 leads to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>The splice mutation in 5 end of intron 5 led to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site can lead to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site has led to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site will lead to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>These data suggested that phosphorylation of the MuSK NPXY site led to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>These data suggested that phosphorylation of the MuSK NPXY site was able to lead to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>These results suggest that the distinct amino termini can lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>These results suggest that the distinct amino termini is able to lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>These results suggest that the distinct amino termini may lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>These results suggested that the distinct amino termini has led to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment leading to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment that leads to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment which has led to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment which leads to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment which led to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>This can lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>This has led to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>This is leading to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>This may lead to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which can lead to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which leads to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele which led to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>This splice mutation in 5 end of intron 5 might has led to abnormal splice in exon 5 and exon 6 and has brought about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>This splice mutation in 5 end of intron 5 might is leading to abnormal splice in exon 5 and exon 6 and bringing about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>This splice mutation in 5 end of intron 5 might led to abnormal splice in exon 5 and exon 6 and brought about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>This that leads to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 that leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 that led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 which can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383 which has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>This, in turn, has led to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>This, in turn, is able to lead to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>This, in turn, is leading to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>This, in turn, led to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>This, in turn, will lead to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, can lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, has led to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, is able to lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, leads to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Transduction of the marA region from a Mar strain, but not a wild-type strain, will lead to loss of OmpF.</text>
                    <arg n="0">Transduction of the marA region from a Mar strain</arg>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which leads to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which led to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which was found to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>We also study in detail a complex splice site mutation, 3332dupl8bp, leading to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>We also study in detail a complex splice site mutation, 3332dupl8bp, which is believed to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase is led to by Crl stimulates the activity of sigma (S).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase was led to by Crl stimulates the activity of sigma (S).</text>
                    <arg n="0">Crl stimulates the activity of sigma (S)</arg>
                    <arg n="1">an increased transcription rate of a subset of genes of the rpoS regulon in stationary phase</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
